231 related articles for article (PubMed ID: 26825642)
1. Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny.
Hines RN; Simpson PM; McCarver DG
Drug Metab Dispos; 2016 Jul; 44(7):959-66. PubMed ID: 26825642
[TBL] [Abstract][Full Text] [Related]
2. Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.
Boberg M; Vrana M; Mehrotra A; Pearce RE; Gaedigk A; Bhatt DK; Leeder JS; Prasad B
Drug Metab Dispos; 2017 Feb; 45(2):216-223. PubMed ID: 27895113
[TBL] [Abstract][Full Text] [Related]
3. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver.
Zhu HJ; Appel DI; Jiang Y; Markowitz JS
Drug Metab Dispos; 2009 Sep; 37(9):1819-25. PubMed ID: 19487248
[TBL] [Abstract][Full Text] [Related]
4. Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2.
Wang J; Williams ET; Bourgea J; Wong YN; Patten CJ
Drug Metab Dispos; 2011 Aug; 39(8):1329-33. PubMed ID: 21540359
[TBL] [Abstract][Full Text] [Related]
5. Presence and inter-individual variability of carboxylesterases (CES1 and CES2) in human lung.
Gabriele M; Puccini P; Lucchi M; Vizziello A; Gervasi PG; Longo V
Biochem Pharmacol; 2018 Apr; 150():64-71. PubMed ID: 29407485
[TBL] [Abstract][Full Text] [Related]
6. Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans.
Yoshida T; Fukami T; Kurokawa T; Gotoh S; Oda A; Nakajima M
Eur J Pharm Sci; 2018 Jan; 111():167-176. PubMed ID: 28966098
[TBL] [Abstract][Full Text] [Related]
7. Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver.
Sato Y; Miyashita A; Iwatsubo T; Usui T
Drug Metab Dispos; 2012 May; 40(5):902-6. PubMed ID: 22293119
[TBL] [Abstract][Full Text] [Related]
8. Effects of alcohol on human carboxylesterase drug metabolism.
Parker RB; Hu ZY; Meibohm B; Laizure SC
Clin Pharmacokinet; 2015 Jun; 54(6):627-38. PubMed ID: 25511794
[TBL] [Abstract][Full Text] [Related]
9. Examination of the carboxylesterase phenotype in human liver.
Ross MK; Borazjani A; Wang R; Crow JA; Xie S
Arch Biochem Biophys; 2012 Jun; 522(1):44-56. PubMed ID: 22525521
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
[TBL] [Abstract][Full Text] [Related]
11. Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation.
Laizure SC; Chen F; Farrar JE; Ali D; Yang B; Parker RB
Drug Metab Pharmacokinet; 2022 Dec; 47():100479. PubMed ID: 36375226
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine reduces CES1, CES2, and CYP3A4 expression through decreasing PXR and increasing DEC1 in HepG2 cells.
Shang W; Liu J; Chen R; Ning R; Xiong J; Liu W; Mao Z; Hu G; Yang J
Xenobiotica; 2016; 46(5):393-405. PubMed ID: 26340669
[TBL] [Abstract][Full Text] [Related]
13. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.
Laizure SC; Parker RB; Herring VL; Hu ZY
Drug Metab Dispos; 2014 Feb; 42(2):201-6. PubMed ID: 24212379
[TBL] [Abstract][Full Text] [Related]
14. Determination of Human Hepatic CYP2C8 and CYP1A2 Age-Dependent Expression to Support Human Health Risk Assessment for Early Ages.
Song G; Sun X; Hines RN; McCarver DG; Lake BG; Osimitz TG; Creek MR; Clewell HJ; Yoon M
Drug Metab Dispos; 2017 May; 45(5):468-475. PubMed ID: 28228413
[TBL] [Abstract][Full Text] [Related]
15. Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597.
Crow JA; Bittles V; Borazjani A; Potter PM; Ross MK
Biochem Pharmacol; 2012 Nov; 84(9):1215-22. PubMed ID: 22943979
[TBL] [Abstract][Full Text] [Related]
16. Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases.
Fukami T; Kariya M; Kurokawa T; Iida A; Nakajima M
Eur J Pharm Sci; 2015 Oct; 78():47-53. PubMed ID: 26164127
[TBL] [Abstract][Full Text] [Related]
17. Differences in Hydrolase Activities in the Liver and Small Intestine between Marmosets and Humans.
Honda S; Fukami T; Hirosawa K; Tsujiguchi T; Zhang Y; Nakano M; Uehara S; Uno Y; Yamazaki H; Nakajima M
Drug Metab Dispos; 2021 Sep; 49(9):718-728. PubMed ID: 34135089
[TBL] [Abstract][Full Text] [Related]
18. Potential Pharmacokinetic Herb-Drug Interactions: Have we Overlooked the Importance of Human Carboxylesterases 1 and 2?
Xu J; Qiu JC; Ji X; Guo HL; Wang X; Zhang B; Wang T; Chen F
Curr Drug Metab; 2019; 20(2):130-137. PubMed ID: 29600756
[TBL] [Abstract][Full Text] [Related]
19. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors.
Thomsen R; Rasmussen HB; Linnet K;
Drug Metab Dispos; 2014 Jan; 42(1):126-33. PubMed ID: 24141856
[TBL] [Abstract][Full Text] [Related]
20. Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro.
Imai S; Ichikawa T; Sugiyama C; Nonaka K; Yamada T
J Pharm Sci; 2019 Feb; 108(2):1027-1034. PubMed ID: 30267780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
